206 related articles for article (PubMed ID: 6436758)
1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
2. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
Jenner P; Taquet H; Mauborgne A; Benoliel JT; Cesselin F; Rose S; Javoy-Agid F; Agid Y; Marsden CD
J Neurochem; 1986 Nov; 47(5):1548-51. PubMed ID: 2428937
[TBL] [Abstract][Full Text] [Related]
3. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden CD
Neurosci Lett; 1989 Jul; 101(3):305-10. PubMed ID: 2505199
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
5. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Close SP; Marriott AS; Pay S
Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
[TBL] [Abstract][Full Text] [Related]
7. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Collins MA; Neafsey EJ
Neurosci Lett; 1985 Apr; 55(2):179-84. PubMed ID: 2582318
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
[TBL] [Abstract][Full Text] [Related]
9. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
[TBL] [Abstract][Full Text] [Related]
10. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
11. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Ueki A; Chong PN; Albanese A; Rose S; Chivers JK; Jenner P; Marsden CD
Neuropharmacology; 1989 Oct; 28(10):1089-97. PubMed ID: 2510050
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
[TBL] [Abstract][Full Text] [Related]
14. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Irifune M; Fukuzaki K; Fukuda T
Neurosci Lett; 1994 Aug; 178(1):95-8. PubMed ID: 7816348
[TBL] [Abstract][Full Text] [Related]
15. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Schultz W; Scarnati E; Sundström E; Tsutsumi T; Jonsson G
Exp Brain Res; 1986; 63(1):216-20. PubMed ID: 3488228
[TBL] [Abstract][Full Text] [Related]
16. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
17. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C; Schingnitz G; Hornykiewicz O
Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
[TBL] [Abstract][Full Text] [Related]
18. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
[TBL] [Abstract][Full Text] [Related]
19. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset.
Fine A; Reynolds GP; Nakajima N; Jenner P; Marsden CD
Neurosci Lett; 1985 Jul; 58(1):123-6. PubMed ID: 3931004
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice.
Heikkila RE; Cabbat FS; Manzino L; Duvoisin RC
Neuropharmacology; 1984 Jun; 23(6):711-3. PubMed ID: 6611514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
